Ms. Franchi brings over 30 years of experience in the biotechnology and life sciences industry to the Dynacure Board. Ms. Franchi currently serves as Chief Financial Officer of Replimune Group Inc. Previously, Ms. Franchi served as the Chief Financial Officer for Merrimack Pharmaceuticals where she streamlined the financial operations while strengthening the balance sheet through the retirement of debt, sales of assets, and navigating the review of strategic alternatives. Prior to Merrimack, Ms. Franchi held the position of Chief Financial Officer at other public and private biotechnology and life sciences companies, including Dimension Therapeutics and Good Start Genetics. Ms. Franchi also spent 16 years at Genzyme (acquired by Sanofi in 2011), holding several positions including Senior Vice President of Finance and Senior Vice President of Corporate Finance in which she played an important role in the approximately $20+ billion acquisition of Genzyme by Sanofi. Ms. Franchi serves on the Boards of Biophytis SA, BioDesix, Inc., and Visioneering Technologies, Inc. Ms. Franchi earned a bachelor’s degree in Business Administration from Hofstra University.